Cellular and Molecular Life Sciences

, Volume 67, Issue 2, pp 239–253 | Cite as

Key factors in mTOR regulation

  • Xiaochun BaiEmail author
  • Yu JiangEmail author


Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that controls a wide range of growth-related cellular processes. In the past several years, many factors have been identified that are involved in controlling mTOR activity. Those factors in turn are regulated by diverse signaling cascades responsive to changes in intracellular and environmental conditions. The molecular connections between mTOR and its regulators form a complex signaling network that governs cellular metabolism, growth and proliferation. In this review, we discuss some key factors in mTOR regulation and mechanisms by which these factors control mTOR activity.


mTOR TSC2 Rheb FKBP38 PRAS40 hVps34 Rag GTPases Phosphatidic acid 



The authors thank their colleagues for stimulating discussion and critical reading of this manuscript. This work was supported by NIH grants CA129821 and GM068832 to YJ.


  1. 1.
    De Virgilio C, Loewith R (2006) Cell growth control: little eukaryotes make big contributions. Oncogene 25:6392–6415PubMedGoogle Scholar
  2. 2.
    Jacinto E, Hall MN (2003) Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4:117–126PubMedGoogle Scholar
  3. 3.
    Heitman J, Movva NR, Hiestand PC, Hall MN (1991) FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 88:1948–1952PubMedGoogle Scholar
  4. 4.
    Koltin Y, Faucette L, Bergsma DJ, Levy MA, Cafferkey R, Koser PL, Johnson RK, Livi GP (1991) Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis–trans isomerase related to human FK506-binding protein. Mol Cell Biol 11:1718–1723PubMedGoogle Scholar
  5. 5.
    Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471–484PubMedGoogle Scholar
  6. 6.
    Huang S, Bjornsti MA, Houghton PJ (2003) Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2:222–232PubMedGoogle Scholar
  7. 7.
    Easton JB, Houghton PJ (2004) Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 8:551–564PubMedGoogle Scholar
  8. 8.
    Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10:457–468PubMedGoogle Scholar
  9. 9.
    Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122–1128PubMedGoogle Scholar
  10. 10.
    Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159–168PubMedGoogle Scholar
  11. 11.
    Bhaskar PT, Hay N (2007) The two TORCs and Akt. Dev Cell 12:487–502PubMedGoogle Scholar
  12. 12.
    Keith CT, Schreiber SL (1995) PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 270:50–51PubMedGoogle Scholar
  13. 13.
    Andrade MA, Bork P (1995) HEAT repeats in the Huntington’s disease protein. Nat Genet 11:115–116PubMedGoogle Scholar
  14. 14.
    Bosotti R, Isacchi A, Sonnhammer EL (2000) FAT: a novel domain in PIK-related kinases. Trends Biochem Sci 25:225–227PubMedGoogle Scholar
  15. 15.
    Dames SA, Mulet JM, Rathgeb-Szabo K, Hall MN, Grzesiek S (2005) The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability. J Biol Chem 280:20558–20564PubMedGoogle Scholar
  16. 16.
    Chen J, Zheng XF, Brown EJ, Schreiber SL (1995) Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 92:4947–4951PubMedGoogle Scholar
  17. 17.
    Chiang GG, Abraham RT (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280:25485–25490PubMedGoogle Scholar
  18. 18.
    Holz MK, Blenis J (2005) Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 280:26089–26093PubMedGoogle Scholar
  19. 19.
    Copp J, Manning G, Hunter T (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69:1821–1827PubMedGoogle Scholar
  20. 20.
    Peterson RT, Beal PA, Comb MJ, Schreiber SL (2000) FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 275:7416–7423PubMedGoogle Scholar
  21. 21.
    Cheng SW, Fryer LG, Carling D, Shepherd PR (2004) Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem 279:15719–15722PubMedGoogle Scholar
  22. 22.
    Acosta-Jaquez HA, Keller JA, Foster KG, Ekim B, Soliman GA, Feener EP, Ballif BA, Fingar DC (2009) Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol Cell Biol 29:4308–4324PubMedGoogle Scholar
  23. 23.
    Rosner M, Siegel N, Valli A, Fuchs C, Hengstschlager M (2009) mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids [Epub ahead of print]Google Scholar
  24. 24.
    Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163–175PubMedGoogle Scholar
  25. 25.
    Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM (2003) GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11:895–904PubMedGoogle Scholar
  26. 26.
    Smith TF, Gaitatzes C, Saxena K, Neer EJ (1999) The WD repeat: a common architecture for diverse functions. Trends Biochem Sci 24:181–185PubMedGoogle Scholar
  27. 27.
    Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11:859–871PubMedGoogle Scholar
  28. 28.
    Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177–189PubMedGoogle Scholar
  29. 29.
    Adami A, Garcia-Alvarez B, Arias-Palomo E, Barford D, Llorca O (2007) Structure of TOR and its complex with KOG1. Mol Cell 27:509–516PubMedGoogle Scholar
  30. 30.
    Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J, Yonezawa K (2003) The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278:15461–15464PubMedGoogle Scholar
  31. 31.
    Schalm SS, Fingar DC, Sabatini DM, Blenis J (2003) TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 13:797–806PubMedGoogle Scholar
  32. 32.
    Hornberger TA, Chu WK, Mak YW, Hsiung JW, Huang SA, Chien S (2006) The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. Proc Natl Acad Sci USA 103:4741–4746PubMedGoogle Scholar
  33. 33.
    Lee VH, Healy T, Fonseca BD, Hayashi A, Proud CG (2008) Analysis of the regulatory motifs in eukaryotic initiation factor 4E-binding protein 1. Febs J 275:2185–2199PubMedGoogle Scholar
  34. 34.
    Tzatsos A (2009) Raptor binds the SAIN (Shc and IRS-1 NPXY-binding) domain of IRS-1 and regulates the phosphorylation of IRS-1 at Ser636/639 by mTOR. J Biol Chem 284(34):22525–22534PubMedGoogle Scholar
  35. 35.
    Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214–226PubMedGoogle Scholar
  36. 36.
    Carriere A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, Roux PP (2008) Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 18:1269–1277PubMedGoogle Scholar
  37. 37.
    Wang L, Lawrence JC Jr, Sturgill TW, Harris TE (2009) Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. J Biol Chem 284:14693–14697PubMedGoogle Scholar
  38. 38.
    Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307–318PubMedGoogle Scholar
  39. 39.
    Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC Jr, Abraham RT (1997) Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99–101PubMedGoogle Scholar
  40. 40.
    Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95:1432–1437PubMedGoogle Scholar
  41. 41.
    Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N (1999) Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13:1422–1437PubMedGoogle Scholar
  42. 42.
    Gingras AC, Raught B, Sonenberg N (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68:913–963PubMedGoogle Scholar
  43. 43.
    Pearson RB, Dennis PB, Han JW, Williamson NA, Kozma SC, Wettenhall RE, Thomas G (1995) The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J 14:5279–5287PubMedGoogle Scholar
  44. 44.
    Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL (1995) Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377:441–446PubMedGoogle Scholar
  45. 45.
    Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, Thomas G (1998) Phosphorylation and activation of p70s6k by PDK1. Science 279:707–710PubMedGoogle Scholar
  46. 46.
    Alessi DR, Kozlowski MT, Weng QP, Morrice N, Avruch J (1998) 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 8:69–81PubMedGoogle Scholar
  47. 47.
    Fingar DC, Salama S, Tsou C, Harlow E, Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16:1472–1487PubMedGoogle Scholar
  48. 48.
    Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ (2001) p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 98:9666–9670PubMedGoogle Scholar
  49. 49.
    Tremblay F, Marette A (2001) Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 276:38052–38060PubMedGoogle Scholar
  50. 50.
    Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166:213–223PubMedGoogle Scholar
  51. 51.
    Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG (2001) Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20:4370–4379PubMedGoogle Scholar
  52. 52.
    Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD (2006) S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 24:185–197PubMedGoogle Scholar
  53. 53.
    Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF (1991) Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352:73–77PubMedGoogle Scholar
  54. 54.
    Craparo A, Freund R, Gustafson TA (1997) 14-3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner. J Biol Chem 272:11663–11669PubMedGoogle Scholar
  55. 55.
    Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125–137PubMedGoogle Scholar
  56. 56.
    Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA, Alessi DR (2007) Identification of protor as a novel rictor-binding component of mTOR complex-2. Biochem J 405:513–522PubMedGoogle Scholar
  57. 57.
    Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296–1302PubMedGoogle Scholar
  58. 58.
    Thedieck K, Polak P, Kim ML, Molle KD, Cohen A, Jeno P, Arrieumerlou C, Hall MN (2007) PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One 2:e1217PubMedGoogle Scholar
  59. 59.
    Woo SY, Kim DH, Jun CB, Kim YM, Haar EV, Lee SI, Hegg JW, Bandhakavi S, Griffin TJ, Kim DH (2007) PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J Biol Chem 282:25604–25612PubMedGoogle Scholar
  60. 60.
    Yang Q, Inoki K, Ikenoue T, Guan KL (2006) Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20:2820–2832PubMedGoogle Scholar
  61. 61.
    Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101PubMedGoogle Scholar
  62. 62.
    Hagan GN, Lin Y, Magnuson MA, Avruch J, Czech MP (2008) A rictor-myo1c complex participates in dynamic cortical actin events in 3T3-L1 adipocytes. Mol Cell Biol 28:4215–4226PubMedGoogle Scholar
  63. 63.
    Martin J, Masri J, Bernath A, Nishimura RN, Gera J (2008) Hsp70 associates with rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun 372:578–583PubMedGoogle Scholar
  64. 64.
    McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell ED, Bally MB, Foster LJ, Dedhar S (2008) Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68:1618–1624PubMedGoogle Scholar
  65. 65.
    Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Konopleva M (2007) Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109:3509–3512PubMedGoogle Scholar
  66. 66.
    Akcakanat A, Singh G, Hung MC, Meric-Bernstam F (2007) Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun 362:330–333PubMedGoogle Scholar
  67. 67.
    Rosner M, Hengstschlager M (2008) Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet 17:2934–2948PubMedGoogle Scholar
  68. 68.
    Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, Lowry C, Newton AC, Mao Y, Miao RQ, Sessa WC, Qin J, Zhang P, Su B, Jacinto E (2008) The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 27:1932–1943PubMedGoogle Scholar
  69. 69.
    Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL (2008) Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 27:1919–1931PubMedGoogle Scholar
  70. 70.
    Garcia-Martinez JM, Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416:375–385PubMedGoogle Scholar
  71. 71.
    Rosner M, Fuchs C, Siegel N, Valli A, Hengstschlager M (2009) Functional interaction of mTOR complexes in regulating mammalian cell size and cell cycle. Hum Mol Genet 18(17):3298–3310PubMedGoogle Scholar
  72. 72.
    Leung AK, Robson WL (2007) Tuberous sclerosis complex: a review. J Pediatr Health Care 21:108–114PubMedGoogle Scholar
  73. 73.
    Mak BC, Yeung RS (2004) The tuberous sclerosis complex genes in tumor development. Cancer Invest 22:588–603PubMedGoogle Scholar
  74. 74.
    Plank TL, Yeung RS, Henske EP (1998) Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 58:4766–4770PubMedGoogle Scholar
  75. 75.
    van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, Reuser A, Sampson J, Halley D, van der Sluijs P (1998) Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 7:1053–1057PubMedGoogle Scholar
  76. 76.
    Wienecke R, Konig A, DeClue JE (1995) Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J Biol Chem 270:16409–16414PubMedGoogle Scholar
  77. 77.
    Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK (2001) The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105:345–355PubMedGoogle Scholar
  78. 78.
    Gao X, Pan D (2001) TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 15:1383–1392PubMedGoogle Scholar
  79. 79.
    Potter CJ, Pedraza LG, Xu T (2002) Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4:658–665PubMedGoogle Scholar
  80. 80.
    Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA (2003) Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol 5:566–571PubMedGoogle Scholar
  81. 81.
    Stocker H, Radimerski T, Schindelholz B, Wittwer F, Belawat P, Daram P, Breuer S, Thomas G, Hafen E (2003) Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol 5:559–565PubMedGoogle Scholar
  82. 82.
    Inoki K, Li Y, Xu T, Guan KL (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17:1829–1834PubMedGoogle Scholar
  83. 83.
    Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5:578–581PubMedGoogle Scholar
  84. 84.
    Castro AF, Rebhun JF, Clark GJ, Quilliam LA (2003) Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 278:32493–32496PubMedGoogle Scholar
  85. 85.
    Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11:1457–1466PubMedGoogle Scholar
  86. 86.
    Li Y, Inoki K, Guan KL (2004) Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol 24:7965–7975PubMedGoogle Scholar
  87. 87.
    Nellist M, Sancak O, Goedbloed MA, Rohe C, van Netten D, Mayer K, Tucker-Williams A, van den Ouweland AM, Halley DJ (2005) Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex. Eur J Hum Genet 13:59–68PubMedGoogle Scholar
  88. 88.
    Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL (2006) Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 173:279–289PubMedGoogle Scholar
  89. 89.
    Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ, Cheng JQ (2002) Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277:35364–35370PubMedGoogle Scholar
  90. 90.
    Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648–657PubMedGoogle Scholar
  91. 91.
    Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10:151–162PubMedGoogle Scholar
  92. 92.
    Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577–590PubMedGoogle Scholar
  93. 93.
    Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15–25PubMedGoogle Scholar
  94. 94.
    Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126:955–968PubMedGoogle Scholar
  95. 95.
    Moon RT (2005) Wnt/beta-catenin pathway. Sci STKE (271):cm1. Accessed 15 Feb 2005Google Scholar
  96. 96.
    Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121:179–193PubMedGoogle Scholar
  97. 97.
    Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D, Cordon-Cardo C, Pandolfi PP (2007) Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 67:7106–7112PubMedGoogle Scholar
  98. 98.
    Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101:13489–13494PubMedGoogle Scholar
  99. 99.
    Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, Gygi SP (2005) Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci USA 102:667–672PubMedGoogle Scholar
  100. 100.
    Yamagata K, Sanders LK, Kaufmann WE, Yee W, Barnes CA, Nathans D, Worley PF (1994) rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein. J Biol Chem 269:16333–16339PubMedGoogle Scholar
  101. 101.
    Kinouchi H, Arai S, Kamii H, Izaki K, Kunizuka H, Mizoi K, Yoshimoto T (1999) Induction of Rheb mRNA following middle cerebral artery occlusion in the rat. Neuroreport 10:1055–1059PubMedGoogle Scholar
  102. 102.
    Bos JL (1997) Ras-like GTPases. Biochim Biophys Acta 1333:M19–M31PubMedGoogle Scholar
  103. 103.
    Aspuria PJ, Tamanoi F (2004) The Rheb family of GTP-binding proteins. Cell Signal 16:1105–1112PubMedGoogle Scholar
  104. 104.
    Im E, von Lintig FC, Chen J, Zhuang S, Qui W, Chowdhury S, Worley PF, Boss GR, Pilz RB (2002) Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 21:6356–6365PubMedGoogle Scholar
  105. 105.
    Yu Y, Li S, Xu X, Li Y, Guan K, Arnold E, Ding J (2005) Structural basis for the unique biological function of small GTPase RHEB. J Biol Chem 280:17093–17100PubMedGoogle Scholar
  106. 106.
    Hsu YC, Chern JJ, Cai Y, Liu M, Choi KW (2007) Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445:785–788PubMedGoogle Scholar
  107. 107.
    Dong X, Yang B, Li Y, Zhong C, Ding J (2009) Molecular basis of the acceleration of the GDP-GTP exchange of human Rheb by human TCTP. J Biol Chem 284(35):23754–23764PubMedGoogle Scholar
  108. 108.
    Smith EM, Finn SG, Tee AR, Browne GJ, Proud CG (2005) The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J Biol Chem 280:18717–18727PubMedGoogle Scholar
  109. 109.
    Roccio M, Bos JL, Zwartkruis FJ (2006) Regulation of the small GTPase Rheb by amino acids. Oncogene 25:657–664PubMedGoogle Scholar
  110. 110.
    Long X, Ortiz-Vega S, Lin Y, Avruch J (2005) Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 280:23433–23436PubMedGoogle Scholar
  111. 111.
    Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY, Gulati P, Byfield MP, Backer JM, Natt F, Bos JL, Zwartkruis FJ, Thomas G (2005) Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 102:14238–14243PubMedGoogle Scholar
  112. 112.
    Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J (2005) Rheb binds and regulates the mTOR kinase. Curr Biol 15:702–713PubMedGoogle Scholar
  113. 113.
    Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25:903–915PubMedGoogle Scholar
  114. 114.
    Sato T, Nakashima A, Guo L, Tamanoi F (2009) Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J Biol Chem 284:12783–12791PubMedGoogle Scholar
  115. 115.
    Tee AR, Blenis J, Proud CG (2005) Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. FEBS Lett 579:4763–4768PubMedGoogle Scholar
  116. 116.
    Marks AR (1996) Cellular functions of immunophilins. Physiol Rev 76:631–649PubMedGoogle Scholar
  117. 117.
    Nielsen JV, Mitchelmore C, Pedersen KM, Kjaerulff KM, Finsen B, Jensen NA (2004) Fkbp8: novel isoforms, genomic organization, and characterization of a forebrain promoter in transgenic mice. Genomics 83:181–192PubMedGoogle Scholar
  118. 118.
    Fischer G, Aumuller T (2003) Regulation of peptide bond cis/trans isomerization by enzyme catalysis and its implication in physiological processes. Rev Physiol Biochem Pharmacol 148:105–150PubMedGoogle Scholar
  119. 119.
    Ratajczak T, Ward BK, Minchin RF (2003) Immunophilin chaperones in steroid receptor signalling. Curr Top Med Chem 3:1348–1357PubMedGoogle Scholar
  120. 120.
    Griffith JP, Kim JL, Kim EE, Sintchak MD, Thomson JA, Fitzgibbon MJ, Fleming MA, Caron PR, Hsiao K, Navia MA (1995) X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82:507–522PubMedGoogle Scholar
  121. 121.
    Kissinger CR, Parge HE, Knighton DR, Lewis CT, Pelletier LA, Tempczyk A, Kalish VJ, Tucker KD, Showalter RE, Moomaw EW et al (1995) Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 378:641–644PubMedGoogle Scholar
  122. 122.
    Maestre-Martinez M, Edlich F, Jarczowski F, Weiwad M, Fischer G, Lucke C (2006) Solution structure of the FK506-binding domain of human FKBP38. J Biomol NMR 34:197–202PubMedGoogle Scholar
  123. 123.
    Pedersen KM, Finsen B, Celis JE, Jensen NA (1999) muFKBP38: a novel murine immunophilin homolog differentially expressed in Schwannoma cells and central nervous system neurons in vivo. Electrophoresis 20:249–255PubMedGoogle Scholar
  124. 124.
    Shirane M, Nakayama KI (2003) Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol 5:28–37PubMedGoogle Scholar
  125. 125.
    Edlich F, Weiwad M, Erdmann F, Fanghanel J, Jarczowski F, Rahfeld JU, Fischer G (2005) Bcl-2 regulator FKBP38 is activated by Ca2+/calmodulin. EMBO J 24:2688–2699PubMedGoogle Scholar
  126. 126.
    Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y, Jiang Y (2007) Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318:977–980PubMedGoogle Scholar
  127. 127.
    Uhlenbrock K, Weiwad M, Wetzker R, Fischer G, Wittinghofer A, Rubio I (2009) Reassessment of the role of FKBP38 in the Rheb/mTORC1 pathway. FEBS Lett 583:965–970PubMedGoogle Scholar
  128. 128.
    Dunlop EA, Dodd KM, Seymour LA, Tee AR (2009) Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein–protein interactions for substrate recognition. Cell Signal 21:1073–1084PubMedGoogle Scholar
  129. 129.
    Ma D, Bai X, Guo S, Jiang Y (2008) The switch I region of Rheb is critical for its interaction with FKBP38. J Biol Chem 283:25963–25970PubMedGoogle Scholar
  130. 130.
    Wang X, Fonseca BD, Tang H, Liu R, Elia A, Clemens MJ, Bommer UA, Proud CG (2008) Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem 283:30482–30492PubMedGoogle Scholar
  131. 131.
    Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N (2009) Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab 296:E592–E602PubMedGoogle Scholar
  132. 132.
    Telerman A, Amson R (2009) The molecular programme of tumour reversion: the steps beyond malignant transformation. Nat Rev Cancer 9:206–216PubMedGoogle Scholar
  133. 133.
    Chen SH, Wu PS, Chou CH, Yan YT, Liu H, Weng SY, Yang-Yen HF (2007) A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Mol Biol Cell 18:2525–2532PubMedGoogle Scholar
  134. 134.
    Rehmann H, Bruning M, Berghaus C, Schwarten M, Kohler K, Stocker H, Stoll R, Zwartkruis FJ, Wittinghofer A (2008) Biochemical characterisation of TCTP questions its function as a guanine nucleotide exchange factor for Rheb. FEBS Lett 582:3005–3010PubMedGoogle Scholar
  135. 135.
    Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, Roth RA (2003) Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 278:10189–10194PubMedGoogle Scholar
  136. 136.
    Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9:316–323PubMedGoogle Scholar
  137. 137.
    Wang L, Harris TE, Roth RA, Lawrence JC Jr (2007) PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282:20036–20044PubMedGoogle Scholar
  138. 138.
    Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A, Eguchi S, Miyamoto T, Hara K, Takehana K, Avruch J, Kikkawa U, Yonezawa K (2007) The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 282:20329–20339PubMedGoogle Scholar
  139. 139.
    Wang L, Harris TE, Lawrence JC Jr (2008) Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J Biol Chem 283:15619–15627PubMedGoogle Scholar
  140. 140.
    Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG (2007) PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 282:24514–24524PubMedGoogle Scholar
  141. 141.
    Dong J, Pan D (2004) Tsc2 is not a critical target of Akt during normal Drosophila development. Genes Dev 18:2479–2484PubMedGoogle Scholar
  142. 142.
    Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB, Salto-Tellez M (2008) Potential roles for the PIM1 kinase in human cancer—a molecular and therapeutic appraisal. Eur J Cancer 44:2144–2151PubMedGoogle Scholar
  143. 143.
    Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS (2009) PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther 8:846–853PubMedGoogle Scholar
  144. 144.
    Li H, Lin X (2008) Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine 41:1–8PubMedGoogle Scholar
  145. 145.
    Häcker H, Karin M (2006) Regulation and function of IKK and IKK-related kinases. Sci STKE (357):re13. Accessed 17 Oct 2006Google Scholar
  146. 146.
    Karin M (1999) How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18:6867–6874PubMedGoogle Scholar
  147. 147.
    Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB (2001) A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 98:4640–4645PubMedGoogle Scholar
  148. 148.
    Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, Hung MC (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130:440–455PubMedGoogle Scholar
  149. 149.
    Dan HC, Baldwin AS (2008) Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol 180:7582–7589PubMedGoogle Scholar
  150. 150.
    Dan HC, Adli M, Baldwin AS (2007) Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res 67:6263–6269PubMedGoogle Scholar
  151. 151.
    Singer WD, Brown HA, Sternweis PC (1997) Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and phospholipase D. Annu Rev Biochem 66:475–509PubMedGoogle Scholar
  152. 152.
    McDermott M, Wakelam MJ, Morris AJ (2004) Phospholipase D. Biochem Cell Biol 82:225–253PubMedGoogle Scholar
  153. 153.
    Andresen BT, Rizzo MA, Shome K, Romero G (2002) The role of phosphatidic acid in the regulation of the Ras/MEK/Erk signaling cascade. FEBS Lett 531:65–68PubMedGoogle Scholar
  154. 154.
    Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J (2001) Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294:1942–1945PubMedGoogle Scholar
  155. 155.
    Sun Y, Chen J (2008) mTOR signaling: PLD takes center stage. Cell Cycle 7:3118–3123PubMedGoogle Scholar
  156. 156.
    Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA (2009) Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 29:1411–1420PubMedGoogle Scholar
  157. 157.
    Fang Y, Park IH, Wu AL, Du G, Huang P, Frohman MA, Walker SJ, Brown HA, Chen J (2003) PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1. Curr Biol 13:2037–2044PubMedGoogle Scholar
  158. 158.
    Ha SH, Kim DH, Kim IS, Kim JH, Lee MN, Lee HJ, Kim JH, Jang SK, Suh PG, Ryu SH (2006) PLD2 forms a functional complex with mTOR/raptor to transduce mitogenic signals. Cell Signal 18:2283–2291PubMedGoogle Scholar
  159. 159.
    Lehman N, Ledford B, Di Fulvio M, Frondorf K, McPhail LC, Gomez-Cambronero J (2007) Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR. Faseb J 21:1075–1087PubMedGoogle Scholar
  160. 160.
    Sun Y, Fang Y, Yoon MS, Zhang C, Roccio M, Zwartkruis FJ, Armstrong M, Brown HA, Chen J (2008) Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci USA 105:8286–8291PubMedGoogle Scholar
  161. 161.
    Exton JH (2002) Regulation of phospholipase D. FEBS Lett 531:58–61PubMedGoogle Scholar
  162. 162.
    Chou MM, Blenis J (1996) The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1. Cell 85:573–583PubMedGoogle Scholar
  163. 163.
    Nishimoto T (2000) Upstream and downstream of ran GTPase. Biol Chem 381:397–405PubMedGoogle Scholar
  164. 164.
    Schurmann A, Brauers A, Massmann S, Becker W, Joost HG (1995) Cloning of a novel family of mammalian GTP-binding proteins (RagA, RagBs, RagB1) with remote similarity to the Ras-related GTPases. J Biol Chem 270:28982–28988PubMedGoogle Scholar
  165. 165.
    Sekiguchi T, Hirose E, Nakashima N, Ii M, Nishimoto T (2001) Novel G proteins, Rag C and Rag D, interact with GTP-binding proteins, Rag A and Rag B. J Biol Chem 276:7246–7257PubMedGoogle Scholar
  166. 166.
    Nakashima N, Noguchi E, Nishimoto T (1999) Saccharomyces cerevisiae putative G protein, Gtr1p, which forms complexes with itself and a novel protein designated as Gtr2p, negatively regulates the Ran/Gsp1p G protein cycle through Gtr2p. Genetics 152:853–867PubMedGoogle Scholar
  167. 167.
    Wang Y, Nakashima N, Sekiguchi T, Nishimoto T (2005) Saccharomyces cerevisiae GTPase complex: Gtr1p-Gtr2p regulates cell-proliferation through Saccharomyces cerevisiae Ran-binding protein, Yrb2p. Biochem Biophys Res Commun 336:639–645PubMedGoogle Scholar
  168. 168.
    Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320:1496–1501PubMedGoogle Scholar
  169. 169.
    Gao M, Kaiser CA (2006) A conserved GTPase-containing complex is required for intracellular sorting of the general amino-acid permease in yeast. Nat Cell Biol 8:657–667PubMedGoogle Scholar
  170. 170.
    Buerger C, DeVries B, Stambolic V (2006) Localization of Rheb to the endomembrane is critical for its signaling function. Biochem Biophys Res Commun 344:869–880PubMedGoogle Scholar
  171. 171.
    Takahashi K, Nakagawa M, Young SG, Yamanaka S (2005) Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway. J Biol Chem 280:32768–32774PubMedGoogle Scholar
  172. 172.
    Schu PV, Takegawa K, Fry MJ, Stack JH, Waterfield MD, Emr SD (1993) Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science 260:88–91PubMedGoogle Scholar
  173. 173.
    Kapeller R, Cantley LC (1994) Phosphatidylinositol 3-kinase. Bioessays 16:565–576PubMedGoogle Scholar
  174. 174.
    Stack JH, Herman PK, Schu PV, Emr SD (1993) A membrane-associated complex containing the Vps15 protein kinase and the Vps34 PI 3-kinase is essential for protein sorting to the yeast lysosome-like vacuole. EMBO J 12:2195–2204PubMedGoogle Scholar
  175. 175.
    Byfield MP, Murray JT, Backer JM (2005) hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 280:33076–33082PubMedGoogle Scholar
  176. 176.
    Gulati P, Gaspers LD, Dann SG, Joaquin M, Nobukuni T, Natt F, Kozma SC, Thomas AP, Thomas G (2008) Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab 7:456–465PubMedGoogle Scholar
  177. 177.
    Stein MP, Feng Y, Cooper KL, Welford AM, Wandinger-Ness A (2003) Human VPS34 and p150 are Rab7 interacting partners. Traffic 4:754–771PubMedGoogle Scholar
  178. 178.
    Drenan RM, Liu X, Bertram PG, Zheng XF (2004) FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus. J Biol Chem 279:772–778PubMedGoogle Scholar
  179. 179.
    Zhang X, Shu L, Hosoi H, Murti KG, Houghton PJ (2002) Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem 277:28127–28134PubMedGoogle Scholar
  180. 180.
    Desai BN, Myers BR, Schreiber SL (2002) FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc Natl Acad Sci USA 99:4319–4324PubMedGoogle Scholar
  181. 181.
    Liu X, Zheng XF (2007) Endoplasmic reticulum and Golgi localization sequences for mammalian target of rapamycin. Mol Biol Cell 18:1073–1082PubMedGoogle Scholar
  182. 182.
    Park IH, Bachmann R, Shirazi H, Chen J (2002) Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. J Biol Chem 277:31423–31429PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag, Basel/Switzerland 2009

Authors and Affiliations

  1. 1.Department of Cell Biology, School of Basic Medical SciencesSouthern Medical UniversityGuangzhouChina
  2. 2.Department of Pharmacology and Chemical BiologyUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations